The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: -1.00 (-2.15%)
Spread: 1.00 (2.222%)
Open: 46.50
High: 45.50
Low: 45.00
Prev. Close: 46.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

Thu, 29th Mar 2018 13:58

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive director Michael Albin will be stepping down from the board effective from Friday.

Albin has 30 years experience in the development and global commercialisation of technologies for the life sciences. Including roles as scientific advisor of Stratos Product Development LLC, vice president for strategic technologies for Applera Corp and as principal scientist at Applied Biosystems.

Albin was granted USD6 million from the National Institute of Standards and Technology for a technology he developed for Applied Biosystems for micro-volume polymerase chain reaction that has been patented and commercialised.

Avacta Chief Executive Officer Alastair Smith said: "I would like to thank Michael for his contribution to the group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael's association with Avacta will continue in an advisory capacity."

Shares in Avacta were trading at 35.10 pence, down 1.1%, Thursday afternoon.

More News
16 Mar 2022 11:38

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

Read more
3 Feb 2022 12:31

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.

Read more
3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Read more
18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

Read more
18 Jan 2022 13:52

Avacta selects potential tumour treatment for preclinical development

Avacta selects potential tumour treatment for preclinical development

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
10 Jan 2022 12:16

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Read more
10 Jan 2022 12:08

Abingdon Health plunges after Avacta stops selling Covid-19 test

Abingdon Health plunges after Avacta stops selling Covid-19 test

Read more
10 Jan 2022 11:29

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Read more
10 Jan 2022 11:05

Shares plummet as Avacta pauses sale of lateral flow tests

(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.

Read more
10 Jan 2022 09:20

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 11:28

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Read more
22 Dec 2021 10:31

Avacta shares up as flow tests receive CE mark for self-test use

Avacta shares up as flow tests receive CE mark for self-test use

Read more
15 Dec 2021 11:56

Avacta confirms lateral flow tests can detect Omicron variant

Avacta confirms lateral flow tests can detect Omicron variant

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.